PH30820A - Use of quinoline-3-carboxamide compounds for treatment of diabetes. - Google Patents

Use of quinoline-3-carboxamide compounds for treatment of diabetes.

Info

Publication number
PH30820A
PH30820A PH45991A PH45991A PH30820A PH 30820 A PH30820 A PH 30820A PH 45991 A PH45991 A PH 45991A PH 45991 A PH45991 A PH 45991A PH 30820 A PH30820 A PH 30820A
Authority
PH
Philippines
Prior art keywords
quinoline
diabetes
treatment
carboxamide compounds
carboxamide
Prior art date
Application number
PH45991A
Other languages
English (en)
Inventor
Slavin Shimon
Weiss Lola
Gross David
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of PH30820A publication Critical patent/PH30820A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH45991A 1992-04-06 1993-04-02 Use of quinoline-3-carboxamide compounds for treatment of diabetes. PH30820A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201076A SE9201076L (sv) 1992-04-06 1992-04-06 Användningen av gamla läkemedel för behandling av diabetes

Publications (1)

Publication Number Publication Date
PH30820A true PH30820A (en) 1997-10-17

Family

ID=20385863

Family Applications (1)

Application Number Title Priority Date Filing Date
PH45991A PH30820A (en) 1992-04-06 1993-04-02 Use of quinoline-3-carboxamide compounds for treatment of diabetes.

Country Status (16)

Country Link
US (1) US5594005A (ja)
EP (1) EP0634931A1 (ja)
JP (1) JPH07506568A (ja)
KR (1) KR950700738A (ja)
CN (1) CN1081671A (ja)
AU (1) AU667362B2 (ja)
CA (1) CA2131831C (ja)
EE (1) EE03090B1 (ja)
HU (1) HUT69710A (ja)
IL (1) IL105285A0 (ja)
NO (1) NO943723L (ja)
NZ (1) NZ251494A (ja)
PH (1) PH30820A (ja)
SE (1) SE9201076L (ja)
WO (1) WO1993019756A1 (ja)
ZA (1) ZA932450B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
FR2827600A1 (fr) * 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2010041908A2 (ko) * 2008-10-09 2010-04-15 (주)뉴트리 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도
AU2011314411B2 (en) * 2010-10-14 2014-06-12 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AhR activators.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use

Also Published As

Publication number Publication date
NZ251494A (en) 1997-07-27
JPH07506568A (ja) 1995-07-20
NO943723D0 (no) 1994-10-05
EE03090B1 (et) 1998-06-15
SE9201076L (sv) 1993-10-07
KR950700738A (ko) 1995-02-20
WO1993019756A1 (en) 1993-10-14
HUT69710A (en) 1995-09-28
CN1081671A (zh) 1994-02-09
AU3913193A (en) 1993-11-08
NO943723L (no) 1994-10-05
AU667362B2 (en) 1996-03-21
HU9402854D0 (en) 1995-01-30
CA2131831C (en) 1999-03-09
CA2131831A1 (en) 1993-10-14
ZA932450B (en) 1993-10-20
US5594005A (en) 1997-01-14
IL105285A0 (en) 1993-08-18
SE9201076D0 (sv) 1992-04-06
EP0634931A1 (en) 1995-01-25

Similar Documents

Publication Publication Date Title
PH24476A (en) Imidazole compounds and biocidal composition comprising the same for controlling harmful organism
GB9215633D0 (en) Novel treatment
AU6425496A (en) Treatment for juvenile diabetes
GB2264235B (en) Composition for nasal treatment
EP0630383A4 (en) METHODS OF TREATING DIABETES.
AU3187595A (en) Compounds for the treatment of restenosis
AU2806692A (en) Medicament for the treatment of anxiety
EP0674707A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF LEUCOMA.
GB9211148D0 (en) Novel treatment
EP0597329A3 (de) Verfahren zur Herstellung von alpha-Fluor -beta-dicarbonylverbindungen.
PH30820A (en) Use of quinoline-3-carboxamide compounds for treatment of diabetes.
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
ZA922386B (en) Use of rapamycin for treating diabetes
ZA951967B (en) Use of Quinoline-3-carboxamide compounds
ZA931063B (en) Treatment of glaucoma.
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
ZA951966B (en) Use of quinoline-3-carboxamide compounds
AU4081393A (en) Medicaments for the treatment of anxiety
EP0609358A4 (en) Methods for treatment of hyperlipidemia using azaspiranes.
EP0583136A3 (en) Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders
EP0453356A3 (en) Process for the oxidation of organic compounds
EP0609335A4 (en) Methods for the treatment of hyperlipidemia using azaspiranes.
AP9300527A0 (en) Novel treatment
ZA93348B (en) Treatment of liquids.
HK1011508A1 (en) Treatment for liquids